You are here
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced or recurrent gastric cancer (JFMC45-1102)
Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al.Int J Cancer 2016 Aug 13. [Epub ahead of print]
Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, et al.Clin Cancer Res 2016 Jun 7 [Epub ahead of print]
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review
Harada K, Baba Y, Shigaki H, Ishimoto T, Miyake K, Kosumi K, et al.BMC Cancer 2016 Jul 7;16:400.
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, et al.Cancer Chemother Pharmacol. 2016 Mar 22. [Epub ahead of print]
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al.BMC Cancer. 2016 Feb 8;16(1):68.
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, et al.Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408.